Skip to main content

Table 2 Description of multiarm clinical trials

From: Drugs and convalescent plasma therapy for COVID-19: a survey of the interventional clinical studies in Italy after 1 year of pandemic

Study acronym  Experimental intervention Sponsor country/Organization Data source Platform  Trial
ACTIVE 4  Dalteparin, Enoxaparin, Heparin, Fondaparin, Tinzaparin Italy AIFA website No
AMMURAVID Remdesivir, Baricitinib, Canakinumab, Methylprednisolone, Sarilumab*, Siltuximab, Tocilizumab Italy AIFA website No
ARCO Darunavir/cobicistat, Favipiravir, Hydroxychloroquine, Lopinavir/Ritonavir Italy AIFA website No
CONVINCE Edoxaban, Colchicine Switzerland, Italy AIFA website No
REMAP-CAP ACE inhibitors, Acetylsalicylic acid, AZD7442, Angiotensin receptor blockers, Clopidogrel, Enoxaparin, Heparin, Interferon-beta-1a, Prasugrel, Sarilumab, Simvastatin, Ticagrelor, Tocilizumab, Vitamin C Netherlands AIFA website Yes
SobiIMMUNO - 101 Emapalumab, Anakinra Italy AIFA website No
SOLIDARITY Chloroquine (or Hydroxychloroquine), Interferon beta-1a, Remdesivir, Lopinavir/Ritonavir WHO AIFA website Yes
STAUNCH Enoxaparin+Methylprednisolone, Heparin+Methylprednisolone Italy AIFA website No
  1. Details of multiarm COVID-19 interventional clinical trials planned to be carried out in Italy (update: 6 April 2021)
  2. *For the study AMMURAVID, the experimental intervention Sarilumab was retrieved from the protocol v3, 17 April 2020. AIFA website [14]